Browse > Article
http://dx.doi.org/10.24304/kjcp.2021.31.1.27

Treatment Patterns of Osteoporosis and Factors Affecting the Prescribing of Bone-forming Agents: From a National Health Insurance Claims Database  

Jeong, Jihae (School of pharmacy, Sungkyunkwan University)
Shin, Ju-Young (School of pharmacy, Sungkyunkwan University)
Publication Information
Korean Journal of Clinical Pharmacy / v.31, no.1, 2021 , pp. 27-34 More about this Journal
Abstract
Objective: To analyze osteoporosis treatment patterns and teriparatide prescription-associated factors in Korea by using a national health insurance claims database. Methods: We utilized the Health Insurance Review & Assessment Service National Patients Sample claims database to identify patients (aged ≥50 years) with at least one osteoporosis claim (International Classification of Disease 10th revision code: M80, M81, M82) and at least one prescription for osteoporosis medication (antiresorptive agents: bisphosphonates, selective estrogen receptor modulators, denosumab, and calcitonin; bone-forming agent: teriparatide) in 2018. Demographic characteristics and healthcare utilization patterns were analyzed. Factors associated with teriparatide prescriptions were assessed using a multivariate logistic regression model. Results: Records showed that 44,815 patients were prescribed osteoporosis medications in 2018; the percentage of patients prescribed each treatment was as follows: 86.6% bisphosphonates, 13.9% selective estrogen receptor modulators, 3.1% calcitonin, 2.1% denosumab, and 0.7% teriparatide. A greater proportion of patients prescribed teriparatide were ≥75 years (53.4% vs. 33.8%) and had fractures (63.9% vs. 12.8%) compared to the same for antiresorptives (p<0.001). Patients prescribed teriparatide had higher Charlson comorbidity index values (1.2±1.3 vs. 0.9±1.2) and were more frequently hospitalized (0.8±1.3 vs. 0.1±0.5) than those prescribed antiresorptives (p<0.001). Elderly patients (≥75 years old; adjusted OR=1.66; 95% CI 1.16-2.38) and those with fractures (adjusted OR=6.23; 95% CI 4.76-8.14) were more likely to be prescribed teriparatide than antiresorptives. Conclusion: Patients prescribed teriparatide were older and more likely to have severe osteoporosis than those prescribed antiresorptives.
Keywords
Osteoporosis; treatment pattern; claims database; teriparatide; bone-forming agents;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Korean Society for Bone and Mineral Research. Osteoporosis and Osteoporotic Fracture Fact Sheet 2019, 1st ed. Seoul: Korean Society for Bone and Mineral Research, 2019; 5-6.
2 Lee EH, Kim W. Socioeconomic Burden of Disease Due to Osteoporosis in South Korea, 1st ed. Suwon: Gyeonggi Research Institue, 2019; 58.
3 Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 2020;26(Suppl 1):1-46.
4 Health Insurance Servie & Assessment Service Bigdata Hub. Guidance for National Sample Claims Database. Available from https://opendata.hira.or.kr/. Accessed December 5, 2020.
5 Kim J, Shin JY, Lee J, Song HJ, Choi NK, Park BJ. Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database. PLoS One 2015;10(6):e0127970.   DOI
6 Kim HY, Ha YC, Kim TY, et al. Healthcare costs of osteoporotic fracture in Korea: Information from the national health insurance claims database, 2008-2011. J Bone Metab 2017;24(2):125-133.   DOI
7 Yoo JI, Ha YC, Park KS, Kim RB, Seo SH, Koo KH. Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 2019;60(10):969-75.   DOI
8 Jang SM, Park CM, Jang SH, et al. Medical service utilization with osteoporosis. Endocrinol Metab 2010;25(4):326-39.   DOI
9 Kamata Y, Minota S. Status quo of osteoporosis treatment in Japan disclosed by the national database of health insurance claims and specific health checkups: too late in treatment initiation and too few in treated patients? Arch Osteoporos 2019;14(1):84.   DOI
10 Foster SA, Foley KA, Meadows ES, et al. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. Osteoporos Int 2008;19(3):373-7.   DOI
11 Korean Society for Bone and Mineral Research. Physician's Guide for Osteoporosis 2018, 1st ed. Seoul: Korean Society for Bone and Mineral Research, 2018; 12, 86-90.